These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
140 related articles for article (PubMed ID: 25990463)
1. Reply to investigating the relationship between vitamin d and cancer requires dosing the bioavailable nonhydroxylated vitamin d storage in cancer tissues. Shui IM; Giovannucci E Cancer; 2015 Sep; 121(18):3363-4. PubMed ID: 25990463 [No Abstract] [Full Text] [Related]
2. Investigating the relationship between vitamin D and cancer requires dosing the bioavailable nonhydroxylated vitamin D storage in cancer tissues. Dreyfus M; Wion D Cancer; 2015 Sep; 121(18):3362-3. PubMed ID: 25990578 [No Abstract] [Full Text] [Related]
3. Vitamin D and cancer: an overview on epidemiological studies. Ordóñez Mena JM; Brenner H Adv Exp Med Biol; 2014; 810():17-32. PubMed ID: 25207358 [TBL] [Abstract][Full Text] [Related]
4. Circulating vitamin D and risk of prostate cancer--letter. Schwartz GG Cancer Epidemiol Biomarkers Prev; 2012 Jan; 21(1):246; author reply 247. PubMed ID: 22045701 [No Abstract] [Full Text] [Related]
5. Vitamin D status: ready for guiding prostate cancer diagnosis and treatment? Grant WB Clin Cancer Res; 2014 May; 20(9):2241-3. PubMed ID: 24789031 [TBL] [Abstract][Full Text] [Related]
6. Circulating vitamin D, vitamin D-related genetic variation, and risk of fatal prostate cancer in the National Cancer Institute Breast and Prostate Cancer Cohort Consortium. Shui IM; Mondul AM; Lindström S; Tsilidis KK; Travis RC; Gerke T; Albanes D; Mucci LA; Giovannucci E; Kraft P; Cancer; 2015 Jun; 121(12):1949-56. PubMed ID: 25731953 [TBL] [Abstract][Full Text] [Related]
7. Associations of vitamin D pathway genes with circulating 25-hydroxyvitamin-D, 1,25-dihydroxyvitamin-D, and prostate cancer: a nested case-control study. Gilbert R; Bonilla C; Metcalfe C; Lewis S; Evans DM; Fraser WD; Kemp JP; Donovan JL; Hamdy FC; Neal DE; Lane JA; Smith GD; Lathrop M; Martin RM Cancer Causes Control; 2015 Feb; 26(2):205-218. PubMed ID: 25488826 [TBL] [Abstract][Full Text] [Related]
8. Vitamin D status and cancer incidence and mortality. Shui I; Giovannucci E Adv Exp Med Biol; 2014; 810():33-51. PubMed ID: 25207359 [TBL] [Abstract][Full Text] [Related]
9. The Fok1 vitamin D receptor gene polymorphism and 25(OH) D serum levels and prostate cancer among Jordanian men. Atoum MF; AlKateeb D; AlHaj Mahmoud SA Asian Pac J Cancer Prev; 2015; 16(6):2227-30. PubMed ID: 25824742 [TBL] [Abstract][Full Text] [Related]
10. A prospective study of plasma 25-hydroxyvitamin D concentration and prostate cancer risk. Deschasaux M; Souberbielle JC; Latino-Martel P; Sutton A; Charnaux N; Druesne-Pecollo N; Galan P; Hercberg S; Le Clerc S; Kesse-Guyot E; Ezzedine K; Touvier M Br J Nutr; 2016 Jan; 115(2):305-14. PubMed ID: 26568368 [TBL] [Abstract][Full Text] [Related]
11. Vitamin D and prostate cancer survival in veterans. Der T; Bailey BA; Youssef D; Manning T; Grant WB; Peiris AN Mil Med; 2014 Jan; 179(1):81-4. PubMed ID: 24402990 [TBL] [Abstract][Full Text] [Related]
12. Vitamin D and prostate cancer risk--a less sunny outlook? Mucci LA; Spiegelman D J Natl Cancer Inst; 2008 Jun; 100(11):759-61. PubMed ID: 18505963 [No Abstract] [Full Text] [Related]
13. Circulating 25-hydroxyvitamin D, vitamin D binding protein and risk of advanced and lethal prostate cancer. Yuan C; Shui IM; Wilson KM; Stampfer MJ; Mucci LA; Giovannucci EL Int J Cancer; 2019 May; 144(10):2401-2407. PubMed ID: 30411792 [TBL] [Abstract][Full Text] [Related]
14. Vitamin D receptor polymorphisms and cancer. Gandini S; Gnagnarella P; Serrano D; Pasquali E; Raimondi S Adv Exp Med Biol; 2014; 810():69-105. PubMed ID: 25207361 [TBL] [Abstract][Full Text] [Related]
15. Vitamin D-related genetic variation, plasma vitamin D, and risk of lethal prostate cancer: a prospective nested case-control study. Shui IM; Mucci LA; Kraft P; Tamimi RM; Lindstrom S; Penney KL; Nimptsch K; Hollis BW; Dupre N; Platz EA; Stampfer MJ; Giovannucci E J Natl Cancer Inst; 2012 May; 104(9):690-9. PubMed ID: 22499501 [TBL] [Abstract][Full Text] [Related]
17. Vitamin D and intervention trials in prostate cancer: from theory to therapy. Schwartz GG Ann Epidemiol; 2009 Feb; 19(2):96-102. PubMed ID: 18619854 [TBL] [Abstract][Full Text] [Related]
18. Associations of circulating 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D, and vitamin D pathway genes with prostate-specific antigen progression in men with localized prostate cancer undergoing active monitoring. Gilbert R; Metcalfe C; Fraser WD; Lewis S; Donovan J; Hamdy F; Neal DE; Lane JA; Martin RM; Tilling K Eur J Cancer Prev; 2013 Mar; 22(2):121-5. PubMed ID: 22955340 [TBL] [Abstract][Full Text] [Related]
19. Randomized clinical trial of vitamin D3 doses on prostatic vitamin D metabolite levels and ki67 labeling in prostate cancer patients. Wagner D; Trudel D; Van der Kwast T; Nonn L; Giangreco AA; Li D; Dias A; Cardoza M; Laszlo S; Hersey K; Klotz L; Finelli A; Fleshner N; Vieth R J Clin Endocrinol Metab; 2013 Apr; 98(4):1498-507. PubMed ID: 23463655 [TBL] [Abstract][Full Text] [Related]
20. Circulating levels of 25-hydroxyvitamin D and prostate cancer prognosis. Holt SK; Kolb S; Fu R; Horst R; Feng Z; Stanford JL Cancer Epidemiol; 2013 Oct; 37(5):666-70. PubMed ID: 23972671 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]